AzurRx BioPharma, Inc. (AZRX): Price and Financial Metrics


AzurRx BioPharma, Inc. (AZRX): $3.45

0.07 (+2.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AZRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AZRX Stock Price Chart Interactive Chart >

Price chart for AZRX

AZRX Price/Volume Stats

Current price $3.45 52-week high $26.30
Prev. close $3.38 52-week low $3.36
Day low $3.38 Volume 629,000
Day high $3.66 Avg. volume 628,703
50-day MA $5.85 Dividend yield N/A
200-day MA $9.42 Market Cap 32.17M

AzurRx BioPharma, Inc. (AZRX) Company Bio


AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company's therapeutic products are administered to patients as oral non-systemic biologics. Its lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.


AZRX Latest News Stream


Event/Time News Detail
Loading, please wait...

AZRX Latest Social Stream


Loading social stream, please wait...

View Full AZRX Social Stream

Latest AZRX News From Around the Web

Below are the latest news stories about AzurRx BioPharma Inc that investors may wish to consider to help them evaluate AZRX as an investment opportunity.

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) IVERIC bio, Inc. (NASDAQ: ISEE ) Leap Therapeutics, Inc. (NASDAQ: LPTX ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 20) Ambrx Biopharma Inc. (NYSE: AMAM ) Absci Corporation (NASDAQ: ABSI ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aytu Biopharma, Inc. (NASDAQ: AYTU ) AzurRx BioPharma, Inc. (NA...

Benzinga | September 22, 2021

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

Company to begin trading on Nasdaq under new ticker symbol, FBWI, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, FBWI, effective September 22

Intrado Digital Media | September 21, 2021

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACH...

Benzinga | September 16, 2021

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company''s website, is as follows:

Intrado Digital Media | September 14, 2021

36 Stocks Moving In Tuesday's Mid-Day Session

Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock. BTCS Inc. (NASDAQ: BTCS) shares climbed 23% to $10.25 as the company commenced trading on The Nasdaq Capital Market. Comm

Yahoo | September 14, 2021

Read More 'AZRX' Stories Here

AZRX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -59.41%
3-year -84.39%
5-year -90.78%
YTD N/A
2021 0.00%
2020 -6.73%
2019 -14.05%
2018 -66.76%
2017 -23.21%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7234 seconds.